Steve Schonfeld’s Black Diamond Therapeutics BDTX Stock Holding History

Steve Schonfeld’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-18,774	Closed	-$40K	–	2621
2026 Q1	$40K	Buy	+18,774	New	+$44.7K	﹤0.01%	1999
2024 Q1	–	Sell	-81,178	Closed	-$228K	–	2070
2023 Q4	$228K	Sell	81,178 -67,922	-46%	-$159K	﹤0.01%	1505
2023 Q3	$428K	Buy	+149,100	New	+$549K	﹤0.01%	1245
2022 Q4	–	Sell	-14,000	Closed	-$23K	–	2596
2022 Q3	$23K	Sell	14,000 -800	-5%	-$2.47K	﹤0.01%	2706
2022 Q2	$37K	Sell	14,800 -5,100	-26%	-$11.9K	﹤0.01%	2259
2022 Q1	$55K	Buy	19,900 +5,200	+35%	+$19K	﹤0.01%	2329
2021 Q4	$78K	Sell	14,700 -200	-1%	-$1.4K	﹤0.01%	1912
2021 Q3	$126K	Sell	14,900 -13,600	-48%	-$134K	﹤0.01%	1887
2021 Q2	$347K	Buy	+28,500	New	+$563K	﹤0.01%	1382
2021 Q1	–	Sell	-33,313	Closed	-$1.07M	–	1795
2020 Q4	$1.07M	Buy	33,313 +25,213	+311%	+$828K	0.01%	789
2020 Q3	$244K	Buy	+8,100	New	+$247K	﹤0.01%	1154

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Steve Schonfeld's BDTX Position: Q2 2026 in Review

Steve Schonfeld sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 18,774 shares — an estimated $40K sold.

Steve Schonfeld first reported a position in BDTX in Q3 2020 and held it in 11 quarters. The position peaked at $1.07M in Q4 2020. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

Steve Schonfeld reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
Steve Schonfeld sold 18,774 Black Diamond Therapeutics shares in Q2 2026, an estimated $40K.
Steve Schonfeld first reported a position in Black Diamond Therapeutics in Q3 2020 and held it in 11 quarters.
Steve Schonfeld's Black Diamond Therapeutics position peaked at $1.07M in Q4 2020.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.